Venetoclax in combination with ponatinib for the treatment of asciminib-resistant chronic myeloid leukemia

Leukemia. 2025 Oct;39(10):2555-2558. doi: 10.1038/s41375-025-02732-1. Epub 2025 Aug 26.

Nikola Curik^#^{1

2}, Adam Laznicka^#^{1

2

3}, Jitka Krizkova¹, Pavla Suchankova¹, Adela Vavrova⁴, Vaclava Polivkova¹, Eva Pokorna², Pavel Semerak^{1

2}, Pavel Burda^{1

2}, Daniela Kuzilkova⁴, Tomas Kalina⁴, Andreas Hochhaus⁵, Katerina Machova Polakova^{6

7}

¹ Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
² Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic.
³ Second Faculty of Medicine, Charles University, Prague, Czech Republic.
⁴ CLIP (Childhood Leukemia Investigation Prague), Department of Pediatric Haematology and Oncology, Second Faculty of Medicine and Faculty Hospital Motol, Charles University, Prague, Czech Republic.
⁵ Abteilung Hämatologie/Onkologie, Klinik für Innere Medizin II, Jena University Hospital, Jena, Germany.
⁶ Institute of Hematology and Blood Transfusion, Prague, Czech Republic. Katerina.Machova@uhkt.cz.
⁷ Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic. Katerina.Machova@uhkt.cz.

^# Contributed equally.

No abstract available